NALDEBAIN® has so far completed a series of preclinical trials, Phase I clinical trials and Phase III clinical trials. It is known from the Phase I clinical trial that the results of the pharmacokinetic test in healthy subjects can predict that the analgesic duration can be at least 7 days, which can support NALDEBAIN® as the basis for the development of long-acting analgesic formulations, and the active ingredients in the blood The concentration profile shows that Natoxide® has a fairly good safety profile.

General analgesic injections can only last for about two to six hours, while Natujie® is a long-acting dosage form made of Nalbuphine pre-drug plus a special formula. After intramuscular injection, it is slowly released and restored to the parent drug Nalbuphine, which is safe The properties and pharmacological effects are the same as the original parent drug, supplemented by a special formula, NALDEBAIN® has a long-term effect of one week, in addition to meeting the clinical needs of long-term pain control of patients, and improving the quality and safety of pain relief for patients , and can effectively reduce the care burden of medical staff and reduce the cost of hospitalization.